VIGAMOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIGAMOX (VIGAMOX).
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
| Metabolism | Not extensively metabolized; systemic absorption is minimal after ophthalmic administration. |
| Excretion | Renal: 70-80% unchanged; biliary/fecal: 15-20% |
| Half-life | Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing |
| Protein binding | 40-50% bound to serum proteins |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution |
| Bioavailability | Ophthalmic: <1% systemic; oral: 80-90% (not clinically used orally) |
| Onset of Action | Ophthalmic: within 30 minutes for conjunctival infection; subconjunctival injection: immediate |
| Duration of Action | Ophthalmic: 12-24 hours after single dose; requires multiple daily dosing for sustained effect |
| Molecular Weight | 437.36 |
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required; drug undergoes minimal systemic absorption. |
| Liver impairment | No adjustment required; drug undergoes minimal systemic absorption. |
| Pediatric use | Children 1 year and older: same as adult dosing; 1 drop every 4 hours while awake for 7 days. |
| Geriatric use | No specific adjustment; use with caution due to potential age-related corneal changes. |
| 1st trimester | Avoid unless benefit outweighs risk. No adequate studies in pregnant women. Animal studies show no evidence of harm at clinically relevant doses. |
| 2nd trimester | Avoid unless benefit outweighs risk. No adequate studies in pregnant women. |
| 3rd trimester | Avoid unless benefit outweighs risk. No adequate studies in pregnant women. Consider risk of arthropathy in neonates. |
Clinical note
Comprehensive clinical and safety monograph for VIGAMOX (VIGAMOX).
| Placental transfer | Unknown, but low molecular weight suggests potential transfer. No data in humans. |
| Breastfeeding | Excreted into breast milk in low amounts; unlikely to cause adverse effects in nursing infants. Consider alternative treatments if available. |
| Lactation Rating |
■ FDA Black Box Warning
Not applicable (ophthalmic use only; systemic fluoroquinolones have boxed warning for tendinitis/tendon rupture, peripheral neuropathy, CNS effects, and myasthenia gravis exacerbation, but VIGAMOX ophthalmic solution does not carry a boxed warning due to minimal systemic absorption).
| Common Effects | Eye discomfort Dry eye Burning sensation in eye |
| Serious Effects |
Hypersensitivity to moxifloxacin or any fluoroquinoloneHistory of tendinopathy with fluoroquinolonesEpidural administration (not indicated)
| Precautions | Prolonged use may result in overgrowth of non-susceptible organisms including fungi., Ophthalmic use only; not for injection., Contact lens wearers should remove lenses during treatment. |
| Food/Dietary | No clinically significant food interactions with ophthalmic moxifloxacin. As minimal systemic absorption occurs, dietary restrictions are not necessary. |
Loading safety data…
| L2: Safer |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, moxifloxacin was not teratogenic in rats or rabbits at doses up to 5 and 20 times the maximum recommended human ophthalmic dose, respectively. However, moxifloxacin caused decreased fetal body weight and increased fetal loss in rats at maternally toxic doses. Use only if potential benefit justifies potential risk to the fetus. Avoid in first trimester if possible due to theoretical risk of arthropathy. |
| Fetal Monitoring | Standard prenatal monitoring. No specific fetal monitoring required. Monitor for maternal signs of hypersensitivity or local ocular adverse effects. |
| Fertility Effects | No human data on fertility effects. In animal studies, moxifloxacin did not impair fertility in rats at oral doses up to 300 mg/kg/day (approximately 6000 times the human ophthalmic dose). |
| Clinical Pearls | Vigamox (moxifloxacin ophthalmic solution) is a fourth-generation fluoroquinolone antibiotic indicated for bacterial conjunctivitis. It achieves high conjunctival tissue concentrations exceeding MIC90 for common pathogens within 10 minutes. Do not use for prophylaxis of neonatal ophthalmia due to lack of data on safety. Avoid soft contact lens wear during treatment. The solution contains no preservative; single-use vials should be discarded after use to prevent contamination. In pediatric patients, adjust dosing interval for infants <1 year of age per package insert. If no clinical improvement within 3 days, reassess diagnosis and consider culture. |
| Patient Advice | Use one drop in the affected eye(s) three times daily for 7 days. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation and wait at least 10 minutes before reinserting. · Discard each single-use vial immediately after use even if some solution remains. · Do not use the solution if it changes color or becomes cloudy. · Report any signs of worsening or severe eye pain, swelling, or visual changes to your healthcare provider. · Do not share the medication with others. · Wash hands before and after instillation. · May cause temporary blurred vision; avoid driving or operating machinery until vision clears. |